Physician profile
Joy Shannon
NPI 1245927052
$2,050.45
in general payments reported to CMS, 2019-2025
18 companies · $639 in 2025
The $639 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,027 · 2024: $384 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $579.46 | 2023-2024 | Injectafer, Vanflyta, Enhertu |
| Astrazeneca Pharmaceuticals LP | $340.01 | 2024-2025 | Calquence |
| Janssen Biotech, INC. | $265.91 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $234.28 | 2023 | Iclusig, Ninlaro |
| Sobi, INC | $143.72 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.29 | 2023 | Opdivo |
| Legend Biotech USA INC. | $98.77 | 2023 | Carvykti |
| Abbvie INC. | $42.16 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $34.29 | 2023 | Monoferric |
| Medtronic, INC. | $31.00 | 2023 | Minimed 780g |
| Adaptive Biotechnologies Corporation | $24.40 | 2025 | Clonoseq |
| Astellas Pharma US INC | $23.97 | 2025 | Cresemba |
| Rare Disease Therapeutics, INC. | $21.67 | 2025 | Xromi |
| Medunik USA INC. | $19.78 | 2025 | Siklos |
| Glaxosmithkline, LLC. | $19.11 | 2025 | Nucala |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $18.66 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2023 | Libtayo |
| Viiv Healthcare Company | $16.32 | 2023 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.